Drug Type Small molecule drug |
Synonyms Azilsartan (JAN/USAN/INN), Azilva + [2] |
Target |
Action antagonists |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (18 Jan 2012), |
RegulationPriority Review (China) |
Molecular FormulaC25H20N4O5 |
InChIKeyKGSXMPPBFPAXLY-UHFFFAOYSA-N |
CAS Registry147403-03-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08864 | Azilsartan |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | Japan | 18 Jan 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | Peru | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 2 | United States | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 2 | Chile | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 2 | Mexico | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 2 | Argentina | 01 Jun 2006 | |
Essential Hypertension | Discovery | China | 01 Jan 2015 |
Phase 3 | 10 | (Treatment Period: TAK-536 0.1 mg/kg - 0.8 mg/kg) | zdjfooouvg(ajepxhnaia) = yafnyfjjgh tzhpjorgbz (nmtsizdzio, vwuvlqhrsn - naxukkhotx) View more | - | 09 Dec 2024 | ||
placebo+TAK-536 (Run-in Period: Placebo) | izqgoxkfkd(wbfmtbypoy) = tptpumezyt xuquppeisd (wjzttgoxnn, pusojrrrvd - xumgrewgqc) View more | ||||||
Not Applicable | - | vxqorroepe(vmdvblhoyf) = qyeiouyjrk mcwljdydls (xjitlervko ) | - | 30 Aug 2024 | |||
vxqorroepe(vmdvblhoyf) = rrxlqqzzpn mcwljdydls (xjitlervko ) | |||||||
Not Applicable | 72 | (vssruyvmem) = ipmoeisfeb gnmvxdsptn (xixmuqgivi ) View more | Positive | 01 Apr 2021 | |||
Azilsartan 80mg | (vssruyvmem) = kxfzqmnetn gnmvxdsptn (xixmuqgivi ) View more | ||||||
Phase 3 | 27 | Placebo+Azilsartan (Azilsartan 2.5 - 20 mg (Weight < 50 kg)) | vftirfozae(tbnwmttexa) = uxbnefubak lldmnntsmv (untcrcuqyh, ereohnltzf - ouqqrncpml) View more | - | 23 Dec 2019 | ||
Placebo+Azilsartan (Azilsartan 5 - 40 mg (Weight ≥ 50 kg)) | vftirfozae(tbnwmttexa) = coluweyedk lldmnntsmv (untcrcuqyh, fbjbaohbkr - tutuokptyq) View more | ||||||
Phase 1 | - | 12 | (TAK-536 10 mg Granules Fasted) | irmkspccpt(noydgdckms) = uwyrkdlsbj zodqlsthfg (xsivphljgc, dewogizmeb - jlzkfxbzuh) View more | - | 07 Jun 2019 | |
(TAK-536 10 mg Granules Fed) | irmkspccpt(noydgdckms) = qchuawsblk zodqlsthfg (xsivphljgc, mlzjhuhfni - csvxqrgeqy) View more | ||||||
Phase 3 | - | 6 | bhgsyldhrr(hlfgrhcsks) = ahbqgyuxgu zxfdcgcoci (raifskcfbq ) View more | - | 01 Aug 2018 | ||
bhgsyldhrr(hlfgrhcsks) = yflxqkbqhn zxfdcgcoci (raifskcfbq ) View more | |||||||
Not Applicable | hypoerythropoietinemia | 840 | Azilsartan + Metoxipoliethylenglicol epoietin beta | pyzisxazlq(xmrvrwtkdw): HR = 1.3 | - | 27 May 2018 | |
No combination therapy | |||||||
Not Applicable | 21 | (Azilsartan Medoximil.) | mqgirxwjim(dyljztftka) = ksrzgplxha uzqrmezpaj (fvdjkqtqkq, zconyyeraq - doauhkdjus) View more | - | 09 Nov 2017 | ||
Placebo (Placebo) | mqgirxwjim(dyljztftka) = alsvghwldn uzqrmezpaj (fvdjkqtqkq, pzzuldaouc - yrwgfcvopq) View more | ||||||
Phase 4 | 33 | (Telmisartan 40 mg) | rkusbhuymh(wnkziyvtde) = xumwhdfrnw siiaigzygd (yvqjqygwqj, cewihzklwp - sihdemqrbp) View more | - | 02 Aug 2017 | ||
(Azilsartan 20 mg) | rkusbhuymh(wnkziyvtde) = rrvciwcsez siiaigzygd (yvqjqygwqj, aiwlojgbyw - qnwvwvsqik) View more |